the spliceosome
/ SPLY-see-oh-some /
Imagine a robotic assembly station on a factory line that has to find the exact joint between two parts, clamp on, make two precise cuts, and weld the parts together — and then disassemble itself and move to the next joint. The spliceosome is that station inside the nucleus, the machine that finds each intron and splices it out of a pre-mRNA.
It is not a single fixed enzyme but a large, dynamic assembly built from five small nuclear RNAs — called U1, U2, U4, U5, and U6 snRNAs — each wrapped in proteins to form a snRNP (a small nuclear ribonucleoprotein, pronounced snurp), plus many additional proteins. The snRNPs recognize the signals at each end of an intron and the branch point inside it, largely by base-pairing their own RNA to the pre-mRNA. They then bend the intron into a loop and assemble step by step into the active spliceosome, which catalyzes two cutting-and-joining reactions before releasing the joined exons and the discarded intron, and then comes apart to be used again.
The deep surprise is what does the actual chemistry. The spliceosome's catalytic heart is RNA, not protein: the snRNAs (especially U2 and U6) position the reacting groups and help drive the bond rearrangements, making the spliceosome a ribozyme. Its architecture closely echoes the self-splicing group II introns, which strongly suggests the spliceosome evolved from such ancient self-splicing RNAs — proteins were recruited later to make the process faster and more controllable, but RNA remains at the core.
U1 snRNP first lands on the intron's 5' GU end by base-pairing, U2 binds the branch point, then U4/U6 and U5 join; rearrangements eject U1 and U4 and switch on the U2-U6 RNA core that does the catalysis. One spliceosome assembles fresh on every intron.
Five snRNPs assemble step by step on each intron; an RNA core, not a protein, does the chemistry.
Mutations that derail the spliceosome cause real disease — for example, certain inherited forms of blindness and some cancers trace to faulty splicing factors. The spliceosome is now a drug target: the medicine that treats spinal muscular atrophy works by nudging the splicing of one specific gene.